

SMAD4 Antibody (T277) Blocking Peptide
Synthetic peptide
Catalog # BP7753a**Specification****SMAD4 Antibody (T277) Blocking Peptide -
Product Information**Primary Accession [Q13485](#)**SMAD4 Antibody (T277) Blocking Peptide -
Additional Information****Gene ID** 4089**Other Names**

Mothers against decapentaplegic homolog 4, MAD homolog 4, Mothers against DPP homolog 4, Deletion target in pancreatic carcinoma 4, SMAD family member 4, SMAD 4, Smad4, hSMAD4, SMAD4, DPC4, MADH4

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7753a](/products/AP7753a) was selected from the T277 region of human SMAD4. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**SMAD4 Antibody (T277) Blocking Peptide -
Protein Information****SMAD4 Antibody (T277) Blocking Peptide -
Background**

SMAD4 is the common SMAD (co-SMAD) mediator of signal transduction by TGF-beta (transforming growth factor). It promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. It may act as a tumor suppressor.

**SMAD4 Antibody (T277) Blocking Peptide -
References**

Sekiya, T., et al., Biochem. Biophys. Res. Commun. 320(3):680-684 (2004). Horvath, L.G., et al., Prostate 59(3):234-242 (2004). Li, L., et al., Mol. Cell. Biol. 24(2):856-864 (2004). Wan, M., et al., J. Biol. Chem. 279(15):14484-14487 (2004). Maru, D., et al., Oncogene 23(3):859-864 (2004).

Name SMAD4**Synonyms** DPC4, MADH4**Function**

In muscle physiology, plays a central role in the balance between atrophy and hypertrophy. When recruited by MSTN, promotes atrophy response via phosphorylated SMAD2/4. MSTN decrease causes SMAD4 release and subsequent recruitment by the BMP pathway to promote hypertrophy via phosphorylated SMAD1/5/8. Acts synergistically with SMAD1 and YY1 in bone morphogenetic protein (BMP)-mediated cardiac- specific gene expression. Binds to SMAD binding elements (SBEs) (5'- GTCT/AGAC-3') within BMP response element (BMPRE) of cardiac activating regions (By similarity). Common SMAD (co-SMAD) is the coactivator and mediator of signal transduction by TGF-beta (transforming growth factor). Component of the heterotrimeric SMAD2/SMAD3-SMAD4 complex that forms in the nucleus and is required for the TGF-mediated signaling (PubMed:25514493). Promotes binding of the SMAD2/SMAD4/FAST-1 complex to DNA and provides an activation function required for SMAD1 or SMAD2 to stimulate transcription. Component of the multimeric SMAD3/SMAD4/JUN/FOS complex which forms at the AP1 promoter site; required for synergistic transcriptional activity in response to TGF- beta. May act as a tumor suppressor. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator.

Cellular Location

Cytoplasm. Nucleus Note=Cytoplasmic in the absence of ligand. Migrates to the nucleus when complexed with R-SMAD (PubMed:15799969). PDPK1 prevents its nuclear translocation in response to TGF-beta (PubMed:17327236)

SMAD4 Antibody (T277) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)